Abstract | BACKGROUND AND PURPOSE: METHODS: Between January 2012 and December 2013, we recorded data from our patients with cerebral venous thrombosis. The modified Rankin scale was used to assess clinical severity; excellent outcome was defined as modified Rankin scale 0 to 1. Recanalization was assessed on follow-up MR angiography. Patients were then divided into 2 treatment groups: phenprocoumon (VKA) and a novel factor Xa inhibitor. Clinical and radiological baseline data, outcome, recanalization status, and complications were retrospectively compared. RESULTS: Sixteen patients were included, and 7 were treated with rivaroxaban. Overall outcome was excellent in 93.8%, and all patients showed at least partial recanalization. No statistical significant differences were found between the groups, except the use of heparin before start of oral anticoagulation (P=0.03). One patient in the VKA and 2 patients in the factor Xa inhibitor group had minor bleeding (P=0.55) within the median (range) follow-up of 8 months (5-26). CONCLUSIONS:
|
Authors | Christina Geisbüsch, Daniel Richter, Christian Herweh, Peter A Ringleb, Simon Nagel |
Journal | Stroke
(Stroke)
Vol. 45
Issue 8
Pg. 2469-71
(Aug 2014)
ISSN: 1524-4628 [Electronic] United States |
PMID | 25070963
(Publication Type: Journal Article)
|
Copyright | © 2014 American Heart Association, Inc. |
Chemical References |
- Anticoagulants
- Factor Xa Inhibitors
- Morpholines
- Thiophenes
- Rivaroxaban
- Phenprocoumon
|
Topics |
- Adolescent
- Adult
- Aged
- Anticoagulants
(therapeutic use)
- Factor Xa Inhibitors
- Female
- Humans
- Male
- Middle Aged
- Morpholines
(therapeutic use)
- Phenprocoumon
(therapeutic use)
- Rivaroxaban
- Sinus Thrombosis, Intracranial
(drug therapy)
- Thiophenes
(therapeutic use)
- Treatment Outcome
- Venous Thrombosis
(drug therapy)
- Young Adult
|